Antibody-functionalized nanoparticles for imaging cancer: Influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice

Contrast Media and Molecular Imaging

Volumn 8, Issue 5, 2013, Pages 402-408

  Karmani, Linda ^a   Labar, Daniel ^a   Valembois, Vanessa ^b   Bouchat, Virginie ^b   Nagaswaran, Praveen Ganesh ^c   Bol, Anne ^a   Gillart, Jacques ^a   Levêque, Philippe ^a   Bouzin, Caroline ^a   Bonifazi, Davide ^c   Michiels, Carine ^b   Feron, Olivier ^a   Grégoire, Vincent ^a   Lucas, Stéphane ^b   Borght, Thierry Vander ^a   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b University of Namur   (Belgium)

^c UNIVERSITY OF NAMUR   (Belgium)

Author keywords

89Zr; Cetuximab targeted gold nanoparticles; EGFR; Immuno PET; Molecular imaging

Indexed keywords

CETUXIMAB; CYANAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GOLD NANOPARTICLE; RADIOISOTOPE; UNCLASSIFIED DRUG; ZIRCONIUM 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CARCINOMA; CHEMICAL REACTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TUMOR LEVEL; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; GOLD; HUMANS; METAL NANOPARTICLES; MICE; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIRCONIUM;

EID: 84879021373     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1539     Document Type: Article

References (37)

1. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther 2010;128:324-335.
2. Mallidi S, Larson T, Aaron J, Sokolov K, Emelianov S. Molecular specific optoacoustic imaging with plasmonic nanoparticles. Opt Express 2007;15:6583-6588.
3. Glaser ES, Massey KL, Zhu C, Curley SA. Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. Surgery 2010;148:319-324.
4. Tiwari PM, Vig K, Dennis VA, Singh R. Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 2011;1:31-63; doi: 10.3390/nano1010031
5. Fay F, Scott CJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 2011;3:381-394.
6. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-385.
7. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-311.
8. Tejani MA, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics 2010;4:173-185; PMID: 20714355
9. Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 suppl 1:S3-17.
10. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett 2006;239:129-135.
11. Sokolov K, Follen M, Aaron J, Pavlova I, Malpica A, Lotan R, Richards-Kortum R. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res 2003;63:1999-2004.
12. Kah JCY, Olivo MC, Lee CGL, Sheppard CJR. Molecular contrast of EGFR expression using gold nanoparticles as a reflectance-based imaging probe. Mol Cell Probes 2008;22:14-23.
13. El-Sayed IH, Huang X, El-Sayed MA. Surface Plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: application in oral cancer. Nano Lett 2005;5:829-834; doi: 10.1021/nl050074e
14. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008;66:274-280.
15. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012;12:39-50; doi: 10.1038/nrc3180
16. 89Zr-labeled compounds for PET imaging guided personalized therapy. Drug Discov Today Technol 2011;8:e53-e61; doi: 10.1016/j.ddtec.2011.12.004.
17. Meijs WE, Haisma HJ, Klok RP, van Gog FB, Kievit E, Pinedo HM, Herscheid JD. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med 1997;38:112-118.
18. Dijkers ECF, Kosterink JGW, Rademaker AP, Perk LR, van Dongen GAMS, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN. Development and characterization of clinical-grade Zr-89-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009;50:974-981; doi: 10.2967/jnumed.108.060392
19. Borjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA, van Dongen GA. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006;12:2133-2140.
20. Borjesson PKE, Jauw YWS, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GA, Boellaard R. Radiation dosimetry of zirconium-89-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 2009;50:1828-1836.
21. van Dongen GAMS, Visser GWM, Lub-de-Hooge MN, De Vries EG, Perk LR. Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist 2007;12:1379-1389.
22. Marrega R, Karmani L, Flamant L, Nageswaran PG, Valembois V, Masereel B, Feron O, Vander Borght T, Lucas S, Michiels C, Gallez B and Bonifazi D. Antibody-functionalized polymer-coated gold nanoparticles targeting cancer cells: an in vivo and in vitro study. J Mater Chem 2012;22:21305-21312.
23. Thorek DLJ, Elias DR and Tsourkas A. Comparative analysis of nanoparticle-antibody conjugations: carbodiimide versus click chemistry. Mol Imag 2009;8:221-229.
24. van Gog FB, Visser GWM, Klok RP, van der Schors R, Snow GB, van Dongen GAMS. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med 1996;37:352-362.
25. Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP, Meares CF. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995;55:878-884.
26. Tinianow JN, Gill HS, Ogasawara A, Flores JE, Vanderbilt AN, Luis E, Vandlen R, Darwish M, Junutula JR, Williams SP, Marik J. Site-specifically Zr-89-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol 2010;37:289-297.
27. Mealey Jr J. Turn-over of carrier-free zirconium-89 in man. Nature 1957;179:673-674; doi: 10.1038/179673a0
28. 89Zr in mice. Nucl Med Biol 2011;38:675-681.
29. Moreau N, Michiels C, Masereel B, Feron O, Gallez B, Vander Borght T, Lucas S. PVD synthesis and transfer into water-based solutions of functionalized gold nanoparticles. Plasma Process Polymer 2009;6:S888-S892; doi: 10.1002/ppap.200932210
30. Holland JP, Sheh YC, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 2009;36:729-739.
31. 89Zr in proton induced reactions on yttrium. J Radioanal Nucl Chem 2007;274:45-52; doi: 10.1007/s10967-006-6892-2
32. 89Zr-labeled monoclonal antibodies. J Nucl Med 2003;44:1271-1281.
33. Vosjan MJWD, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Prot 2010;5:739-743.
34. Perk LR, Vosjan MJWD, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imag 2010;37:250-259.
35. Masereel B, Dinguizli M, Bouzin C, Moniotte N, Feron O, Gallez B, Vander Borght T, Michiels C, Lucas S. Antibody immobilization on gold nanoparticles coated layer-by-layer with polyelectrolytes. J Nanopart Res 2011;13:1573-1580.
36. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, Leigh BR, Cai W. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imag 2011;38:1335-1343.
37. Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imag 2007;34:532-540.